MedTrace Logo

Heparinized Islets in Clinical Islet Transplantation

NCT00678990 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-12-10

No results posted yet for this study

Summary

In this study the islets will be surface modified to carry immobilised heparin (Corline Heparin Conjugate) prior to transplantation. The primary objective is to investigate safety and efficacy of allogeneic islet transplantation using islets coated with immobilised heparin. The modification with heparin has been shown to protect the islets from being attacked by the immediate defence systems in blood (coagulation and inflammation), so that a larger portion of the islets will survive the initial phase and engraft. Evaluation will be based on metabolic and blood chemistry parameters.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

PROCEDURE

Transplantation of islets with heparin coating

Transplantation of islets with heparin coating

Sponsors & Collaborators

  • Corline Biomedical AB

    lead INDUSTRY

Principal Investigators

  • Tomas Lorant · Uppsala University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00678990 on ClinicalTrials.gov